… of individualized therapy. In this article we review clinical data for molecular-targeted
therapies in NSCLC, with emphasis on EGF-R, VEGF-R and other novel targets. Nonetheless, for …

… shift in the management of non-small cell lung cancer (NSCLC). NSCLC should now be …
without a known driver mutation, targeted therapy is pushing the boundary to significantly …

… Here, we review the development of targeted therapies for the treatment of advanced or
metastatic NSCLC, including those already in clinical practice and those in early trials. The …

… on the rationale for the development of targeted therapies in NSCLC and the various strategies
employed in preventing or overcoming the inevitable occurrence of treatment resistance. …

… Here, we discuss both established and emerging targeted therapy approaches, as well as
ongoing challenges for the treatment of NSCLC patients harboring oncogenic alterations of …

… resistance to these targeted therapies. We review recent progress in the development of
targeted treatments for patients with advanced non-small-cell lung cancer, especially focusing …

… treatment for patients with lung cancer and the promise of precision medicine, with special
emphasis on new targeted therapies. … groups require special treatment considerations and no …

… for the treatment of metastatic non–small cell lung cancer (… of tumor biology, numerous
targeted agents have emerged to address the apparent plateau achieved with cytotoxic therapy. In …

… aimed at these abnormalities are already in the clinic. This Review outlines the current
state-of-the-art research for targeted therapy … and also discusses other targeted therapies that are …

… To date, no targeted therapy has been approved for use in the treatment of patients with …
that several new targeted agents, such as antiangiogenic agents and mammalian target of …